- Market Realist•1 hour ago
With 80% of the total patients on antiretroviral therapy using the company’s HIV drugs in the US, Gilead Sciences (GILD) continues to be a leading player in the HIV segment.
- Investor's Business Daily•2 hours ago
When Peter Gassner started Veeva in 2007, he had one primary goal -- replace biopharma companies' legacy systems with cloud-based software.
|Bid||124.74 x 300|
|Ask||124.75 x 400|
|52wk Range||81.79 - 126.07|
|Day's Range||124.34 - 125.00|
|Avg Vol (3m)||7,006,617|
As of 10:10 AM EDT. NYSE Real Time Price. Market open.